Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.
TapImmune released some interesting results this week from a Phase I trial conducted at the Mayo Clinic that will add some spice to that discussion.
TPIV200 vaccine candidate showed 90% of patients developed robust and durable antigen-specific immune responses against FRa.
TapImmune, an immuno-oncology company in Florida is currently clinically testing a vaccine specifically for triple-negative breast and ovarian cancer.
A novel therapeutic vaccine, TPIV200, is being investigated in a new randomized, multicenter, double-blinded, placebo-controlled phase II clinical trial in patients with triple-negative breast cancer (TNBC).
Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.
Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.
With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.
TPIV 200 is a vaccine that the immuno-oncology company TapImmune is developing as a treatment for platinum-chemotherapy resistant ovarian cancer or triple-negative breast cancer.
TapImmune’s lead candidate, TPIV200, a multiple-epitope anti-folate receptor alpha (FRα) immunotherapy, with an FDA orphan drug designation, has paired up with AstraZeneca’s checkpoint inhibitor Imfinzi in platinum-resistant ovarian cancer patients.
Tapimmune Inc. President & CEO, Peter Hoang, participates in an interview with The Wall Street Analyzer. Take a listen.